Frontiers in Cardiovascular Medicine · Oct 31, 2026
Effects of renal denervation on glycemic outcomes in patients with hypertension: a systematic review and meta-analysis
By Shuyi Wu, Tianjiao Lyu, Rongxue Xiao et al.
BackgroundRenal denervation (RDN) lowers blood pressure in uncontrolled or resistant hypertension, but whether it produces a treatment-specific glycemic effect remains unclear. We conducted a systematic review and meta-analysis using controlled between-group comparisons as the primary evidence framework.MethodsPubMed, Embase, and Web of Science were searched from January 2008 to January 2026. Prespecified glycemic outcomes included fasting glucose, HbA1c, fasting insulin, 2-h OGTT glucose, HOMA-IR, and C-peptide. Controlled between-group comparisons were prioritized, whereas RDN-arm before–after analyses were considered exploratory. Systolic and diastolic blood pressure were evaluated as reference outcomes. Exploratory study-level analyses examined whether baseline metabolic burden was associated with fasting-glucose changes.ResultsTwenty-four studies comprising 2,565 participants were included. Controlled analyses showed no significant between-group differences in fasting glucose (MD, −0.30 mmol/L; 95% CI, −0.73 to 0.14), HbA1c, fasting insulin, or HOMA-IR. Evidence for 2-h OGTT glucose and C-peptide was insufficient for controlled analysis. Exploratory RDN-arm before-after analyses suggested reductions in fasting glucose and HOMA-IR, but these findings were not reproduced in controlled comparisons. Controlled analyses demonstrated reductions in systolic and diastolic blood pressure. Exploratory study-level analyses suggested larger fasting-glucose reductions in populations with greater baseline metabolic burden, but these findings were sensitive to individual-study exclusions.ConclusionsRDN lowered blood pressure, but current controlled evidence does not support a universal glucose-lowering effect. Exploratory findings suggest that baseline metabolic status may be related to fasting-glucose changes after RDN, although a treatment-specific benefit remains unproven. Adequately powered controlled trials in metabolically high-risk populations with prespecified primary glycemic endpoints and baseline-risk stratification are needed.Systematic review registration: PROSPERO, CRD420251047804, https://www.crd.york.ac.uk/PROSPERO/view/CRD420251047804.